Literature DB >> 8106779

Prevalence of Neisseria meningitidis relatively resistant to penicillin in the United States, 1991. Meningococcal Disease Study Group.

L A Jackson1, F C Tenover, C Baker, B D Plikaytis, M W Reeves, S A Stocker, R E Weaver, J D Wenger.   

Abstract

To estimate the prevalence of Neisseria meningitidis relatively resistant to penicillin in the United States, antimicrobial susceptibility testing was performed on all US meningococcal isolates submitted to the Centers for Disease Control and Prevention in 1991, including isolates identified through population-based surveillance for invasive meningococcal disease in selected areas of the United States. Three of the 100 isolates tested had MICs of penicillin of 0.125 microgram/mL. All were serogroup B, beta-lactamase-negative, and unique by multilocus enzyme electrophoresis subtyping. None of the 3 patients had been treated solely with penicillin; all recovered completely. About 4% of the isolates obtained from the population-based surveillance system were relatively penicillin-resistant. Given the low prevalence and uncertain clinical significance of infection with these organisms, routine susceptibility testing of meningococcal isolates is not indicated at this time; however, continued surveillance is necessary to monitor trends in antimicrobial susceptibility of meningococci in the United States.

Entities:  

Mesh:

Year:  1994        PMID: 8106779     DOI: 10.1093/infdis/169.2.438

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  16 in total

1.  Disc testing of meningococci.

Authors:  J Campos
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

2.  Pattern of bacterial meningitis in Italy, 1994.

Authors:  S Salmaso; P Mastrantonio; G Scuderi; M E Congiu; T Stroffolini; M G Pompa; S Squarcione
Journal:  Eur J Epidemiol       Date:  1997-04       Impact factor: 8.082

3.  Surveillance of antimicrobial resistance in Neisseria meningitidis from patients in the Cincinnati tristate region (Ohio, Kentucky, and Indiana).

Authors:  Joel E Mortensen; Mary Jo Gerrety; Larry D Gray
Journal:  J Clin Microbiol       Date:  2006-04       Impact factor: 5.948

Review 4.  Prospects for vaccine prevention of meningococcal infection.

Authors:  Lee H Harrison
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

5.  Comparison of broth microdilution and E-test for susceptibility testing of Neisseria meningitidis.

Authors:  A Pascual; P Joyanes; L Martinez-Martinez; A I Suarez; E J Perea
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

Review 6.  Update on meningococcal disease with emphasis on pathogenesis and clinical management.

Authors:  M van Deuren; P Brandtzaeg; J W van der Meer
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

7.  Bacterial meningitis: epidemiology, pathogenesis and management update.

Authors:  Yuliya Nudelman; Allan R Tunkel
Journal:  Drugs       Date:  2009       Impact factor: 9.546

8.  In vitro activities of ciprofloxacin, cefotaxime, ceftriaxone, chloramphenicol, and rifampin against fully susceptible and moderately penicillin-resistant Neisseria meningitidis.

Authors:  J M Blondeau; Y Yaschuk
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

9.  Antibody responses to the capsular polysaccharide of Neisseria meningitidis serogroup B in patients with meningococcal disease.

Authors:  D M Granoff; S K Kelsey; H A Bijlmer; L Van Alphen; J Dankert; R E Mandrell; F H Azmi; R J Scholten
Journal:  Clin Diagn Lab Immunol       Date:  1995-09

10.  Neisseria meningitidis with decreased susceptibility to penicillin in Saskatchewan, Canada.

Authors:  J M Blondeau; F E Ashton; M Isaacson; Y Yaschuck; C Anderson; G Ducasse
Journal:  J Clin Microbiol       Date:  1995-07       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.